Contrasting Pasithea Therapeutics (NASDAQ:KTTA) and CSL (OTCMKTS:CSLLY)

CSL (OTCMKTS:CSLLY) and Pasithea Therapeutics (NASDAQ:KTTA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.

Volatility and Risk

CSL has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Pasithea Therapeutics has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500.

Valuation and Earnings

This table compares CSL and Pasithea Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CSL	$15.56 billion	3.09	$3.00 billion	N/A	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43 million	($3.57)	-0.20

CSL has higher revenue and earnings than Pasithea Therapeutics.

Insider and Institutional Ownership

0.0% of CSL shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 2.0% of Pasithea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares CSL and Pasithea Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CSL	N/A	N/A	N/A
Pasithea Therapeutics	N/A	-85.48%	-77.42%

Analyst Ratings

This is a breakdown of recent ratings for CSL and Pasithea Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CSL	0	2	0	1	2.67
Pasithea Therapeutics	2	0	1	0	1.67

Pasithea Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 318.24%. Given Pasithea Therapeutics’ higher possible upside, analysts plainly believe Pasithea Therapeutics is more favorable than CSL.

Summary

CSL beats Pasithea Therapeutics on 7 of the 11 factors compared between the two stocks.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

About Pasithea Therapeutics

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.